Owner
U
UntitledVerification
Tags
ANTI-EPILEPTIC DRUGS (AEDs)
Full PK + PD + Toxicity + Pregnancy/Gynecology relevance
ANTI-EPILEPTIC DRUGS (AEDs) — COMPLETE MASTER COMPARISON TABLE (ZERO OMISSION)
I. SODIUM CHANNEL BLOCKERS
Drug | Pharmacodynamics (PD) | Pharmacokinetics (PK) | Toxicity / Adverse Effects | Pregnancy & OB-GYN Relevance | Key Exam Anchors |
Carbamazepine | Use-dependent block of voltage-gated Na⁺ channels → ↓ high-frequency neuronal firing | Slow absorption; auto-induces CYP enzymes; highly protein-bound; hepatic metabolism | Diplopia, ataxia; SIADH → hyponatremia; bone marrow suppression; hepatotoxicity; Stevens-Johnson syndrome (↑ risk with HLA-B1502) | Avoid if alternatives exist; neural tube defects (folate deficiency); CYP induction → ↓ OCP efficacy → breakthrough bleeding; folic acid supplementation required | CYP inducer; reduces OCP efficacy; Na⁺ channel blocker |
Phenytoin | Use-dependent inhibition of Na⁺ channels | Non-linear (zero-order) kinetics at high doses; highly protein-bound; CYP metabolism; saturable metabolism → toxicity | Acute: nystagmus, ataxia, diplopia, sedation Chronic: gingival hyperplasia, hirsutism, peripheral neuropathy, megaloblastic anemia (↓ folate), osteomalacia (↓ Vit-D) | Teratogenic – fetal hydantoin syndrome (cleft lip/palate, nail hypoplasia); CYP induction ↓ OCPs; supplement folate + vitamin D | Zero-order kinetics = classic exam line |
Lamotrigine | Na⁺ channel block; ↓ glutamate release → membrane stabilization | Good oral absorption; hepatic glucuronidation; ↓ levels with enzyme inducers; ↑ levels with valproate | Rash (common early); Stevens–Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN); dizziness, ataxia, diplopia, headache, GI upset | One of the safest AEDs in pregnancy; small ↑ oral cleft risk; pregnancy ↑ clearance → ↓ levels → seizure risk; monitor levels each trimester; postpartum dose reduction; estrogen OCPs ↓ levels; breastfeeding usually safe | First-line AED in pregnancy; watch rash |
Lacosamide | Enhances slow inactivation of Na⁺ channels | Hepatic metabolism | Dizziness; PR-interval prolongation | Limited data; not first-line | Slow Na⁺ inactivation |
II. GABA-RELATED AEDs
Drug | Pharmacodynamics | Pharmacokinetics | Toxicity | Pregnancy / OB-GYN | Exam Anchors |
Valproate / Sodium Valproate | ↑ GABA (↓ degradation + ↑ synthesis); blocks Na⁺ channels; blocks T-type Ca²⁺ channels | High oral bioavailability; hepatic metabolism; high protein binding | Hepatotoxicity (fatal risk in children); pancreatitis; tremor; weight gain; alopecia; thrombocytopenia | Strong teratogen; neural tube defects (spina bifida); cognitive impairment; avoid in women of child-bearing age; if unavoidable → high-dose folic acid | Most dangerous AED in pregnancy |
Benzodiazepines (midazolam, diazepam, lorazepam) | Potentiate GABA-A → ↑ frequency of Cl⁻ channel opening | Hepatic metabolism; active metabolites | Sedation; tolerance; dependence | Avoid chronic use; neonatal withdrawal risk | Status epilepticus drugs |
Phenobarbital | ↑ duration of GABA-A channel opening | Hepatic metabolism; long half-life | Sedation; cognitive slowing; CYP induction | Teratogenic; neonatal bleeding (vit-K deficiency) | Barbiturate = duration |
III. CALCIUM CHANNEL BLOCKERS
Drug | Pharmacodynamics | Pharmacokinetics | Toxicity | Pregnancy | Exam Anchor |
Ethosuximide | Blocks T-type Ca²⁺ channels in thalamic neurons | Oral; hepatic metabolism | GI upset; fatigue; headache; rare SJS | Safer than valproate for absence seizures | DOC for absence seizures |
IV. BROAD-SPECTRUM AEDs
Drug | Pharmacodynamics | Pharmacokinetics | Toxicity | Pregnancy | Exam Anchor |
Topiramate | Na⁺ channel block; ↑ GABA; AMPA glutamate antagonism | Renal elimination | Weight loss; kidney stones; cognitive impairment; paresthesias | ↑ cleft lip risk | Weight loss + stones |
Levetiracetam | Binds Synaptic Vesicle protein 2A → modulates vesicle release | Renal elimination; minimal interactions | Behavioral changes (irritability); sedation | One of the safest AEDs in pregnancy; breastfeeding safe | Minimal drug interactions |
V. MIDAZOLAM (HIGH-YIELD BENZODIAZEPINE)
Feature | Details |
Drug class | Benzodiazepine |
Mechanism | GABA-A potentiation → ↑ frequency of Cl⁻ opening |
Uses | Procedural sedation; anxiolysis; status epilepticus; anesthesia adjunct |
Onset | IV: 1–5 min; short duration |
Metabolism | Hepatic (CYP3A4); active metabolites |
Side effects | Respiratory depression, hypotension, anterograde amnesia, paradoxical agitation |
Interactions | Opioids ↑ respiratory depression |
Reversal | Flumazenil |
Exam lines | Short-acting benzo; anterograde amnesia |
VI. HIGH-YIELD PHARMACOKINETIC THEMES
Theme | Drugs |
CYP inducers | Phenytoin, Carbamazepine, Phenobarbital |
OCP failure risk | Carbamazepine, Phenytoin, Phenobarbital |
Renal elimination | Levetiracetam, Topiramate, Gabapentin, Pregabalin |
High protein binding | Valproate, Phenytoin |
Non-linear kinetics | Phenytoin |
VII. KEY PHARMACODYNAMIC THEMES
Mechanism | Drugs |
Na⁺ channel block | Phenytoin, Carbamazepine, Lamotrigine, Valproate, Topiramate, Lacosamide |
↑ GABA | Valproate, Benzodiazepines, Phenobarbital, Vigabatrin |
Ca²⁺ channel block | Ethosuximide (T-type), Gabapentin, Pregabalin |
VIII. AEDs & PREGNANCY — OBGYN GOLD TABLE
Category | Drugs |
Highest teratogenic risk | Valproate (worst), Phenytoin, Carbamazepine, Phenobarbital |
Relatively safer | Lamotrigine, Levetiracetam, Carbamazepine (if needed) |
Teratogenic effects | Neural tube defects, cleft lip/palate, CHD, limb defects, developmental delay |
Folic acid | Mandatory (high dose) |
Pregnancy PK change | Lamotrigine clearance ↑ → dose escalation required |
OCP failure | CYP-inducing AEDs |
IX. BREASTFEEDING COMPATIBILITY
Safe | Caution |
Valproate, Carbamazepine, Lamotrigine, Levetiracetam | Phenobarbital (excess infant sedation) |
X. EXAM QUICK-RECALL LOCKS
- Ethosuximide → absence seizures
- Valproate → Na⁺ + Ca²⁺ + ↑ GABA
- Phenytoin → zero-order kinetics
- Lamotrigine → safest in pregnancy
- CYP-inducing AEDs → OCP failure
- Benzos → frequency, barbiturates → duration
1. Sodium channel blockers
(mainstay for focal + generalized tonic–clonic)
CARBAMAZEPINE
Pharmacodynamics
- Use-dependent block of voltage-gated sodium channels
- Reduces high-frequency neuronal firing
Pharmacokinetics
- Absorption slow
- Auto-induction of liver enzymes (CYP inducer)
- Highly protein-bound
- Hepatic metabolism
Toxicity
- Diplopia
- Ataxia
- SIADH → hyponatremia
- Bone marrow suppression
- Hepatotoxicity
- Stevens-Johnson syndrome, esp. in HLA-B1502 carriers
Pregnancy/Gyne relevance
- Contraindicated in pregnancy if alternatives exist
- Neural tube defects (folate deficiency risk)
- CYP induction lowers OCP effectiveness,breakthrough bleeding
- Supplement folic acid
PHENYTOIN
Pharmacodynamics
- Use-dependent inhibition of sodium channels
Pharmacokinetics
- Non-linear (zero-order) kinetics at higher doses
- Highly protein bound
- CYP metabolism
- Saturable metabolism → toxicity risk
Toxicity
Acute
- Nystagmus
- Ataxia
- Diplopia
- Sedation
Chronic
- Gingival hyperplasia
- Hirsutism
- Peripheral neuropathy
- Megaloblastic anemia (folate interference)
- Osteomalacia (Vit-D metabolism interfered)
Pregnancy/Gyne
- Teratogenic: fetal hydantoin syndrome
- Cleft lip/palate, nail hypoplasia
- CYP induction ↓ OCPs
- Supplement folate + vitamin D
LAMOTRIGINE
Pharmacodynamics
- Blocks sodium channels
- Inhibits glutamate release
Pharmacokinetics
- Hepatic glucuronidation
- Levels ↓ with enzyme inducers (carbamazepine, phenytoin)
- Levels ↑ with valproate
Toxicity
- Rash → can progress to Stevens-Johnson syndrome
- Dizziness
- Blurred vision
Pregnancy relevance
- Relatively safe
- First-line in pregnancy for generalized seizures
LACOSAMIDE
PD: enhances slow inactivation sodium channels
PK: hepatic metabolism
Toxicity: dizziness, PR-interval prolongation
Lamotrigine
Classification & Uses
- Antiepileptic / mood stabilizer
- Used for:
- Focal seizures
- Generalized tonic-clonic seizures
- Lennox-Gastaut syndrome
- Bipolar disorder (especially depression-prevention)
Mechanism of action
- Blocks voltage-gated sodium channels
- ↓ presynaptic glutamate release
- Stabilizes neuronal membranes
→ prevents repetitive firing
Pharmacokinetics
- Oral absorption good
- Hepatic metabolism (glucuronidation)
- Serum levels affected strongly by other drugs:
- Valproate ↓ metabolism → ↑ lamotrigine levels
- Enzyme inducers (phenytoin, carbamazepine) ↑ metabolism → ↓ levels
Adverse effects (important)
- Rash (most common early)
- Severe hypersensitivity:
- Stevens-Johnson syndrome (SJS)
- Toxic epidermal necrolysis (rare)
- Dizziness
- Ataxia
- Diplopia
- Headache
- GI upset
Risk factors for serious rash
- Rapid dose escalation
- Concomitant valproate therapy
- Younger age
- History of rash with AEDs
Drug interactions
- Valproate ↑ lamotrigine concentration (reduce dose)
- Estrogen-containing contraceptives ↑ clearance → ↓ lamotrigine levels
OB-GYN / Pregnancy relevance (very exam important)
Safety in pregnancy
- Considered one of the safer AEDs in pregnancy
- Lower teratogenicity risk compared to valproate/carbamazepine
- Main risk: oral clefts in 1st trimester (small increased risk)
Dosing considerations in pregnancy
- Pregnancy ↑ glucuronidation → ↑ clearance of lamotrigine
- Requires:
- Baseline serum level before conception
- Monitor level each trimester
- Dose upward as needed
- Reduce dose postpartum to avoid toxicity
→ levels fall → seizures may worsen
Breastfeeding
- Appears in breastmilk, infant exposure moderate
- Usually compatible; monitor infants for:
- Rash
- Poor feeding
- Excess sleepiness
Contraception effects
- Estrogen OCPs ↓ lamotrigine levels
- May require higher lamotrigine dose
- Levels fluctuate during pill-free week → toxicity risk
Bipolar disorder in pregnancy context
- Preferred mood stabilizer option in pregnancy for bipolar depression prophylaxis
- Safer alternative to valproate / lithium for teratogenicity concerns
Epilepsy considerations in pregnancy
- Avoid abrupt discontinuation
- Discuss folic acid before conception
- Maintain seizure control to prevent maternal/fetal complications
Quick memory anchors
- Lamotrigine = Na+ channel blocker + anti-glutamate
- Safer in pregnancy, but levels fall → monitor + adjust
- Watch for rash → SJS especially when combined with valproate
- OCPs ↓ lamotrigine levels
If you want next:
- comparison table vs valproate/carbamazepine in pregnancy
- dose adjustment algorithm during pregnancy
- visual mind-map version
- exam-style MCQs on lamotrigine in pregnancy
2. GABA-related drugs
VALPROATE / SODIUM VALPROATE
Pharmacodynamics
- Increases GABA levels (inhibits degradation + enhances synthesis)
- Blocks sodium channels
- Blocks T-type calcium channels
Pharmacokinetics
- High oral bioavailability
- Hepatic metabolism
- High protein binding
Toxicity
- Hepatotoxicity (fatal risk in children)
- Pancreatitis
- Tremor
- Weight gain
- Alopecia
- Thrombocytopenia
Pregnancy risk
- Strong teratogen
- Neural tube defects → spina bifida
- Cognitive impairment risk
OB guidance
- Avoid in pregnancy when possible
- Not first-line for women of child-bearing age
- If required: high-dose folic acid
BENZODIAZEPINES (midazolam, diazepam, lorazepam)
PD
- Potentiate GABA-A mediated chloride influx
- Used in status epilepticus
PK
- Hepatic metabolism
- Active metabolites
Toxicity
- Sedation
- Tolerance/dependence
Pregnancy
- Avoid chronic use; neonatal withdrawal risk
BARBITURATES (phenobarbital)
PD: increases GABA duration of channel opening
PK: hepatic metabolism, long half-life
Toxicity: sedation, cognitive slowing, CYP induction
Pregnancy
- Teratogenic; bleeding risk in newborn (vit K deficiency)
3. Calcium channel blockers
ETHOSUXIMIDE
PD
- Blocks T-type calcium channels in thalamic neurons
- Drug of choice for absence seizures
PK
- Oral, hepatic metabolism
Toxicity
- GI upset
- Fatigue
- Headache
- Stevens-Johnson rare
Pregnancy
- safer than valproate for absence seizures
4. Broad spectrum (useful for focal + generalized)
TOPIRAMATE
PD
- Sodium channel block
- Enhances GABA
- Antagonizes AMPA glutamate receptors
PK
- Renal elimination
Toxicity
- Weight loss
- Kidney stones
- Cognitive impairment
- Paresthesias
Pregnancy
- Cleft lip risk
LEVETIRACETAM
PD
- Binds SV2A → modulates neurotransmitter vesicle release
PK
- Renal elimination
- Minimal drug interactions
Toxicity
- Behavioral changes (irritability)
- Sedation
Pregnancy
- One of safest AEDs in pregnancy
HIGH-YIELD PHARMACOKINETICS THEMES
Hepatic metabolism + CYP inducers
- phenytoin
- carbamazepine
- phenobarbital
CYP induction reduces hormonal contraceptive effectiveness
- use reliable contraception counseling
Renal elimination
- levetiracetam
- topiramate
- gabapentin
- pregabalin
Protein binding concerns
- valproate
- phenytoin
Non-linear PK
- phenytoin
KEY PHARMACODYNAMICS THEMES
Block sodium channels
- phenytoin
- carbamazepine
- lamotrigine
- valproate
- topiramate
- lacosamide
Increase GABA
- valproate
- benzodiazepines
- phenobarbital
- vigabatrin
Block calcium channels
- ethosuximide (T-type)
- gabapentin/pregabalin (voltage-gated)
AEDs AND PREGNANCY – OBGYN GOLD POINTS
- Highest teratogenic risk
- valproate (most dangerous)
- phenytoin
- carbamazepine
- phenobarbital
- Relatively safer AEDs (use in pregnancy)
- lamotrigine
- levetiracetam
- carbamazepine (if necessary)
- AED teratogenic effects
- neural tube defects
- cleft lip/palate
- congenital heart disease
- limb defects
- developmental delay
- Folic acid supplementation mandatory
- High dose for any woman on AEDs
- AED levels change in pregnancy
- Lamotrigine clearance increases → seizure breakthrough possible → adjust dose
- OCP failure risk with CYP inducers
- carbamazepine, phenytoin, phenobarbital
COUNSELLING = essential gyne exam line
BREASTFEEDING + AEDs
Generally compatible except high doses of sedating drugs
- valproate safe
- carbamazepine safe
- lamotrigine safe
- levetiracetam safe
- avoid phenobarbital if infant excessive sedation
EXAM QUICK RECALL LINES
- Ethosuximide = absence seizures
- Valproate blocks Na, Ca, ↑GABA
- Phenytoin = zero-order kinetics
- Lamotrigine safest in pregnancy
- CYP-inducing AEDs reduce OCP efficacy
If you want next:
- Anti-epileptic drug MCQs with answers
- Status epilepticus emergency algorithm
- AED therapeutic drug monitoring table
- AED drug interactions master chart
Midazolam – High-Yield Summary
Drug class
- Benzodiazepine
Key mechanism
- Enhances the effect of the inhibitory neurotransmitter GABA-A
- Increases frequency of Cl⁻ channel opening → hyperpolarizes neurons → CNS depression
(Easy memory: benzos = frequency, barbiturates = duration.)
Uses
Common medical uses:
- Procedural sedation (endoscopy, minor surgeries)
- Anxiolysis before procedures
- Status epilepticus (as an anticonvulsant)
- Induction for anesthesia (adjunct)
- Muscle relaxation
Administration / onset
- IV: rapid onset 1–5 min
- IM, oral routes also used
- Duration shorter than diazepam
Metabolism
- Liver metabolism via CYP3A4
- Active metabolites
Side effects
Most important:
- Respiratory depression
- Hypotension
- Anterograde amnesia
- Paradoxical agitation (especially kids)
- Drowsiness
Important interaction
- Potentiated by opioids → ↑ respiratory suppression risk
- Reversed by flumazenil (competitive antagonist)
Contraindications / cautions
- Severe respiratory insufficiency/ sleep apnea
- Elderly – increased sensitivity
- Liver failure → prolonged effect
Exam one-liners
- Midazolam is a short-acting benzodiazepine used for procedural sedation.
- Works by GABA-A potentiation increasing Cl⁻ influx.
- Causes anterograde amnesia and respiratory depression.
- Flumazenil reverses benzodiazepine sedation.
